pembrolizumab,ipilimumab,nivolumab
bms,merck
['prosper,trial', 'kn564', 'checkmate 914', 'rcc,(-irccs),(-srcc),(-urcc)', 'check,mate,914']
prof larkin discusses adjuvant io in rcc. so far, kn564 is positice (but os is immature), prosper and checkmate 914 are negative. is adjuvant treatment necessary or more toxic than anything else? same io effect at relapse? the right trial hasn't been designed...
#esmo2022 
Enjoying oncology, without meaning to sound too cynical